Clinical and biochemical parameters during neuroleptic treatment. II. Antipsychotic effect of haloperidol in patients with chronic organic brain damage.
The time-course of psychopathological symptoms, of extrapyramidal side effects, and of changes in cerebrospinal fluid (CSF) concentration of homovanillic acid (HVA) and 5-hydroxyindoleacetic acid (5-HIAA) were simultaneously studied during Haloperidol treatment of 14 psychotic patients with chronic organic brain damage. After 15 days of treatment significant antipsychotic effect was found, while Parkinsonism scores in clinical and experimental tests increased only slightly. CSF concentration of HVA increased significantly by 150% compared to the baseline value (p less than 0.05) and 5-HIAA remained unchanged. No correlation was found between the clinical and biochemical variables studied. The comparison of these results with those obtained in patients without brain damage suggests that different psychopathological and extrapyramidal responses to neuroleptics are not strictly associated with specific HVA changes in CSF.
D000328:Adult; D000368:Aged; D001925:Brain Damage, Chronic / Q000150:complications; D003863:Depression / Q000209:etiology; D005260:Female; D006212:Hallucinations; D006220:Haloperidol / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid*; D006801:Humans; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid*; D008297:Male; D008875:Middle Aged; D010259:Paranoid Disorders / Q000188:drug therapy / Q000209:etiology*; D010302:Parkinson Disease, Secondary / Q000139:chemically induced; D010648:Phenylacetates / Q000134:cerebrospinal fluid*; D013577:Syndrome
D010648:Phenylacetates; D006897:Hydroxyindoleacetic Acid; D006220:Haloperidol; D006719:Homovanillic Acid